Tatva Chintan Pharma Chem: September ’22 Results Update
Moneylife Digital Team 14 November 2022
Tatva Chintan Pharma Chem (Tatva) continued its poor performance in Q2FY22-23. Revenue declined by 27% y-o-y (year-on-year) to Rs90 crore because sales of SDA (structure directing agent) declined by 88% y-o-y on disruption in auto production due to chip shortage and 50% drop in sales of heavy-duty diesel engine commercial vehicles (CVs) in China. SDA’s revenue contribution fell to just 11% in...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback